231 related articles for article (PubMed ID: 26194993)
1. A dangerous method? The use of induced pluripotent stem cells as a model for schizophrenia.
Jacobs BM
Schizophr Res; 2015 Oct; 168(1-2):563-8. PubMed ID: 26194993
[TBL] [Abstract][Full Text] [Related]
2. Application of induced pluripotent stem cells to understand neurobiological basis of bipolar disorder and schizophrenia.
Liu YN; Lu SY; Yao J
Psychiatry Clin Neurosci; 2017 Sep; 71(9):579-599. PubMed ID: 28393474
[TBL] [Abstract][Full Text] [Related]
3. Disease signatures for schizophrenia and bipolar disorder using patient-derived induced pluripotent stem cells.
Watmuff B; Berkovitch SS; Huang JH; Iaconelli J; Toffel S; Karmacharya R
Mol Cell Neurosci; 2016 Jun; 73():96-103. PubMed ID: 26777134
[TBL] [Abstract][Full Text] [Related]
4. Understanding neurodevelopmental disorders using human pluripotent stem cell-derived neurons.
Tamburini C; Li M
Brain Pathol; 2017 Jul; 27(4):508-517. PubMed ID: 28585386
[TBL] [Abstract][Full Text] [Related]
5. Stemming the hype: what can we learn from iPSC models of Parkinson's disease and how can we learn it?
Jacobs BM
J Parkinsons Dis; 2014; 4(1):15-27. PubMed ID: 24398656
[TBL] [Abstract][Full Text] [Related]
6. Differentiation efficiency of induced pluripotent stem cells depends on the number of reprogramming factors.
Löhle M; Hermann A; Glass H; Kempe A; Schwarz SC; Kim JB; Poulet C; Ravens U; Schwarz J; Schöler HR; Storch A
Stem Cells; 2012 Mar; 30(3):570-9. PubMed ID: 22213586
[TBL] [Abstract][Full Text] [Related]
7. Modeling developmental neuropsychiatric disorders with iPSC technology: challenges and opportunities.
Young-Pearse TL; Morrow EM
Curr Opin Neurobiol; 2016 Feb; 36():66-73. PubMed ID: 26517284
[TBL] [Abstract][Full Text] [Related]
8. Back and forth in time: Directing age in iPSC-derived lineages.
Cornacchia D; Studer L
Brain Res; 2017 Feb; 1656():14-26. PubMed ID: 26592774
[TBL] [Abstract][Full Text] [Related]
9. Abnormal neuronal differentiation and mitochondrial dysfunction in hair follicle-derived induced pluripotent stem cells of schizophrenia patients.
Robicsek O; Karry R; Petit I; Salman-Kesner N; Müller FJ; Klein E; Aberdam D; Ben-Shachar D
Mol Psychiatry; 2013 Oct; 18(10):1067-76. PubMed ID: 23732879
[TBL] [Abstract][Full Text] [Related]
10. Advances in the understanding of the pathophysiology of schizophrenia and bipolar disorder through induced pluripotent stem cell models.
Perrottelli A; Marzocchi FF; Caporusso E; Giordano GM; Giuliani L; Melillo A; Pezzella P; Bucci P; Mucci A; Galderisi S
J Psychiatry Neurosci; 2024; 49(2):E109-E125. PubMed ID: 38490647
[TBL] [Abstract][Full Text] [Related]
11. Generating induced pluripotent stem cell derived endothelial cells and induced endothelial cells for cardiovascular disease modelling and therapeutic angiogenesis.
Clayton ZE; Sadeghipour S; Patel S
Int J Cardiol; 2015 Oct; 197():116-22. PubMed ID: 26123569
[TBL] [Abstract][Full Text] [Related]
12. Understanding the molecular basis of autism in a dish using hiPSCs-derived neurons from ASD patients.
Lim CS; Yang JE; Lee YK; Lee K; Lee JA; Kaang BK
Mol Brain; 2015 Sep; 8(1):57. PubMed ID: 26419846
[TBL] [Abstract][Full Text] [Related]
13. Stem cell-derived neurons in the development of targeted treatment for schizophrenia and bipolar disorder.
Watmuff B; Liu B; Karmacharya R
Pharmacogenomics; 2017 Apr; 18(5):471-479. PubMed ID: 28346060
[TBL] [Abstract][Full Text] [Related]
14. Human pluripotent stem cells as tools for neurodegenerative and neurodevelopmental disease modeling and drug discovery.
Corti S; Faravelli I; Cardano M; Conti L
Expert Opin Drug Discov; 2015 Jun; 10(6):615-29. PubMed ID: 25891144
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological studies using iPSC-derived neurons from patients with schizophrenia].
Nakazawa T
Nihon Yakurigaku Zasshi; 2021; 156(4):220-223. PubMed ID: 34193699
[TBL] [Abstract][Full Text] [Related]
16. Utilizing induced pluripotent stem cells (iPSCs) to understand the actions of estrogens in human neurons.
Shum C; Macedo SC; Warre-Cornish K; Cocks G; Price J; Srivastava DP
Horm Behav; 2015 Aug; 74():228-42. PubMed ID: 26143621
[TBL] [Abstract][Full Text] [Related]
17. A potential role for insulin-like growth factor signaling in induction of pluripotent stem cell formation.
Li Y; Geng YJ
Growth Horm IGF Res; 2010 Dec; 20(6):391-8. PubMed ID: 20956084
[TBL] [Abstract][Full Text] [Related]
18. Contribution of induced pluripotent stem cell technologies to the understanding of cellular phenotypes in schizophrenia.
Balan S; Toyoshima M; Yoshikawa T
Neurobiol Dis; 2019 Nov; 131():104162. PubMed ID: 29729395
[TBL] [Abstract][Full Text] [Related]
19. Cellular reprogramming to reset epigenetic signatures.
Hewitt KJ; Garlick JA
Mol Aspects Med; 2013; 34(4):841-8. PubMed ID: 22982217
[TBL] [Abstract][Full Text] [Related]
20. Modeling schizophrenia with iPS cell technology and disease mouse models.
Nakazawa T
Neurosci Res; 2022 Feb; 175():46-52. PubMed ID: 34411680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
